BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional and country-levels. METHODS: Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These data were combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV. RESULTS: There are an estimated 6.1 million [95% uncertainty interval (UI) = 3.4-9.2] people with recent injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic prevalence; UI = 31.6-47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI = 1.0-2.1), eastern Europe (1.5 million, UI = 0.7-2.4) and North America (1.0 million, UI = 0.4-1.7). People with recent injecting drug use comprise an estimated 8.5% (UI = 4.6-13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI = 11.7-56.7), Latin America (22.0%, UI = 15.3-30.4) and eastern Europe (17.9%, UI = 8.2-30.9). CONCLUSIONS: Although, globally, 39.2% of people with recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among people with recent injecting drug use, there is wide variation among countries and regions.
BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional and country-levels. METHODS: Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These data were combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV. RESULTS: There are an estimated 6.1 million [95% uncertainty interval (UI) = 3.4-9.2] people with recent injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic prevalence; UI = 31.6-47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI = 1.0-2.1), eastern Europe (1.5 million, UI = 0.7-2.4) and North America (1.0 million, UI = 0.4-1.7). People with recent injecting drug use comprise an estimated 8.5% (UI = 4.6-13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI = 11.7-56.7), Latin America (22.0%, UI = 15.3-30.4) and eastern Europe (17.9%, UI = 8.2-30.9). CONCLUSIONS: Although, globally, 39.2% of people with recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among people with recent injecting drug use, there is wide variation among countries and regions.
Authors: Bradley M Mathers; Louisa Degenhardt; Benjamin Phillips; Lucas Wiessing; Matthew Hickman; Steffanie A Strathdee; Alex Wodak; Samiran Panda; Mark Tyndall; Abdalla Toufik; Richard P Mattick Journal: Lancet Date: 2008-09-23 Impact factor: 79.321
Authors: Maryam Alavi; Jesse D Raffa; Gregory D Deans; Calvin Lai; Mel Krajden; Gregory J Dore; Mark W Tyndall; Jason Grebely Journal: Liver Int Date: 2013-11-20 Impact factor: 5.828
Authors: Meghan D Morris; Stephen Shiboski; Julie Bruneau; Judith A Hahn; Margaret Hellard; Maria Prins; Andrea L Cox; Gregory Dore; Jason Grebely; Arthur Y Kim; Georg M Lauer; Andrew Lloyd; Thomas Rice; Naglaa Shoukry; Lisa Maher; Kimberly Page Journal: Clin Infect Dis Date: 2017-04-01 Impact factor: 9.079
Authors: Jason Grebely; Gregory J Dore; Sébastien Morin; Jürgen K Rockstroh; Marina B Klein Journal: J Int AIDS Soc Date: 2017-07-28 Impact factor: 5.396
Authors: Sunil Suhas Solomon; Thomas C Quinn; Suniti Solomon; Allison M McFall; Aylur K Srikrishnan; Vinita Verma; Muniratnam S Kumar; Oliver Laeyendecker; David D Celentano; Syed H Iqbal; Santhanam Anand; Canjeevaram K Vasudevan; Shanmugam Saravanan; David L Thomas; Kuldeep Singh Sachdeva; Gregory M Lucas; Shruti H Mehta Journal: J Hepatol Date: 2019-10-08 Impact factor: 25.083
Authors: Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely Journal: Liver Int Date: 2018-09-22 Impact factor: 5.828
Authors: Adam Trickey; Hannah Fraser; Aaron G Lim; Amy Peacock; Samantha Colledge; Josephine G Walker; Janni Leung; Jason Grebely; Sarah Larney; Natasha K Martin; Matthew Hickman; Louisa Degenhardt; Margaret T May; Peter Vickerman Journal: Lancet Gastroenterol Hepatol Date: 2019-04-10
Authors: Andreea A Artenie; Evan B Cunningham; Gregory J Dore; Brian Conway; Olav Dalgard; Jeff Powis; Philip Bruggmann; Margaret Hellard; Curtis Cooper; Philip Read; Jordan J Feld; Behzad Hajarizadeh; Janaki Amin; Karine Lacombe; Catherine Stedman; Alain H Litwin; Pip Marks; Gail V Matthews; Sophie Quiene; Amanda Erratt; Julie Bruneau; Jason Grebely Journal: Clin Infect Dis Date: 2020-05-23 Impact factor: 9.079
Authors: Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney Journal: Lancet Date: 2019-10-23 Impact factor: 79.321